World Drug Discovery Technologies Market

World Drug Discovery Technologies Market

This report analyzes the worldwide markets for Drug Discovery Technologies in Millions of US$. The specific technology types analyzed are Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics, and Other Drug Discovery Technologies (Include Combinatorial Chemistry, Nanotechnology and RNAi). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe and Rest of World. Annual forecasts are provided for each region for the period of 2001 through 2015. The report profiles 187 companies including many key and niche players worldwide such as Abbott Laboratories, Affymetrix Inc., Agilent Technologies Inc., Albany Molecular Research, Inc., Amersham Biosciences, Applera Corporation, ArQule Inc., AstraZeneca, BD Biosciences, Bio-Rad Laboratories, Inc., BioSciences Group, Caliper Life Sciences, Inc., Capital GenomiX, Caprion Pharmaceuticals Inc., Charles River Laboratories International, Inc., ChemBridge Corporation, deCODE Genetics, Inc., Evotec AG, Galapagos NV, Incyte Corporation (Formerly Incyte Genomics, Inc.), Infinity Pharmaceuticals, Inc., Invitrogen Corporation, Medarex, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., National Center for Drug Screening, PerkinElmer, Inc., Pharmacopeia Inc., Proteome Systems, Quantum Pharmaceuticals, Shimadzu Corporation, Sigma-Aldrich, Tecan Group, Thallion Pharmaceuticals, Inc. and Tripos, International. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

DRUG DISCOVERY TECHNOLOGIES MCP-1506
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Bioanalytical Instruments I-4
Nuclear Magnetic Resonance I-4
Mass Spectroscopy I-4
Microplate Readers I-4
Chemotherapy Instruments I-4
High Throughput Screening (HTS) I-4
Genomics I-4
Proteomics I-4
Bioinformatics I-5
Biochip I-5
Pharmacogenomics I-5
Other Drug Discovery Technologies I-5


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Drug Discovery Outsourcing - A Necessity II-1
Current & Future Analysis II-1
Analysis by Geographic Region II-1
Analysis by Technology Type II-2

2. An Overview of Key Emerging Technologies II-3
Bioinformatics II-3
Pharmacogenomics II-3
Theragnostics II-4
Targeted Therapy II-5
Mass Spectrometry - A New Catalyst for Technological Developments II-5

3. Market Trends II-8
New Technologies Fire Up Drug Discovery Market II-8
Obesity Related Diseases Driving Drug Discovery Research II-8
Biochips Change Face of Drug Discovery II-8
Genomics and Proteomics Gaining Prominence II-8
Genomics Drives Bioinformatics Growth in Drug Discovery II-9
Market Scenario of Human Genome Sciences (HGS) II-9
International Initiatives Expand Proteomics II-9

4. Drug Discovery - An Overview II-10
Drug Discovery - Definition II-10
Drug Discovery Process II-10
Drug Discovery Technologies II-11
Bioanalytical Instruments II-11
Nuclear Magnetic Resonance II-11
Mass Spectroscopy II-11
Microplate Readers II-11
Chemotherapy Instruments II-12
High Throughput Screening II-12
Genomics II-12
Functional Genomics II-12
Structural Genomics II-12
Proteomics II-12
Classification of Proteomics II-13
Bioinformatics II-13
Categories of Bioinformatics II-13
Advantages of Bioinformatics in Drug Discovery II-13
Market Highlights II-13
Biochip II-14
Types of Biochips II-14
Pharmacogenomics II-14
A Revolutionary Health Care Therapy II-15
Other Drug Discovery Technologies II-16
Combinatorial Chemistry II-16
Lab-on-a-Chip II-16
RNA Interference II-17

5. Product Launches II-18
Affymetrix Introduces Cytogenetic Solution II-18
Affymetrix Introduces DMET Early Access Solution II-18
Affymetrix Microarray Platform to feature in Pathwork’s
Diagnostic Test II-18
Bio-Rad Laboratories Rolls Out Vasculitis Kit for BioPlex 2200
System II-18
PerkinElmer Develops Products for High-Throughput Screening II-19
Tecan to Introduce Multimode Microplate Reader- Infinite M1000 II-19
Waters Introduces Next-Generation MS System - Synapt™ II-19
Tripos International Launches SYBYL®8.0 II-19
Bio-Rad Laboratories Unveils In2it A1C Analyzer for Diabetic
Patients II-20
Charles River Launches Endosafe®-MCS™ Endotoxin Detection System II-20
Invitrogen Launches Human Embryonic Stem Cells Monitoring Kit II-20
Sigma-Aldrich Introduces Proteomics Dynamic Range Standard II-21
Molecular Devices Develops Arcturus (XT) ™ LMC Instrument II-21
Fujitsu’s BioSciences Renames CAChe Software and Releases
Scigress Explorer™ II-21
Tripos International Unveils Topomer CoMFA® II-21
Tripos International Launches Topomer Search II-21
Sigma-Aldrich Introduces GenomePlex® II-22
Agilent Unveils Dual Mode Microarray Platform II-22
Molecular Devices Launches ImageXpressULTRA™ II-22
Applied Biosystems Commercializes TaqMan® Influenza II-22
Agilent Launches Assay Kits for Lab-On-a-Chip Platform II-22
Affymetrix Unveils GeneChip® Microarrays II-23
Quantum Introduces Drug Discovery Software II-23
Invitrogen Launches Stealth™ RNAi Human Kinase Collection II-23
PerkinElmer Unveils BioXPRESSION™ II-23
Affymetrix and ParAllele Jointly Introduce MegAllele™ Assays II-23
Agilent Launches HD-CGH Custom Microarrays II-23
Applied Biosystems and MDS Sciex Unveil Tempo™ LC II-24
Beckman Coulter Presents Chemistry Analyzer for Clinical Testing II-24
Molecular Devices Launches ADME Assay Kits II-24
Applied Biosystems Unveils LS*LIMS™ Software II-24
Affymetrix Presents NimbleExpress™ II-24
Agilent Releases Software for Pharma QC/QA II-24

6. Recent Industry Activity II-25
Affymetrix Acquires USB Corp II-25
Roche Acquires Ventana Medical Systems II-25
Bruker BioSciences Acquires Bruker BioSpin Group II-25
Takeda Signs Agreement to Take Over Millennium II-25
Pfizer to Acquire Serenex II-26
Implant Sciences to Acquire Ion Metrics II-26
NascaCell and Archemix Expand Partnership for Aptamer-Based Drugs II-27
DiscoveRx and Cosmo Bio Sign Distribution Agreement II-27
Zydus Cadila Enters into Collaboration with Prolong
Pharmaceuticals II-28
PsychoGenics Enters into Drug Discovery Agreement with Dainippon II-28
Zydus Cadila Collaborates with Karo Bio II-28
Nicholas Piramal’s R&D Unit Extends Alliance with Eli Lilly II-29
Dr. Reddy’s Signs Collaboration Agreement with 7TM Pharma II-29
Synamatix Enters into Collaboration with Universiti Malaysia II-30
Monogram Enters into Exclusive Collaboration Agreement with Avexa II-30
Caliper Life Sciences Collaborates with Horizon Discovery II-31
Galapagos Signs Collaborative Agreement with Allergan for Drug
Discovery II-31
Sigma-Aldrich Inks Exclusive Distribution Partnership with
Atlas Antibodies II-31
PsychoGenics Enters into New Agreement with Eli Lilly II-32
Ambrx and Eli Lilly Enter into Alliance for Drug Discovery II-32
BioSeek Enters into Agreement with Dainippon Sumitomo II-32
NicOx Extends Collaboration with Pfizer II-33
BioFocus DPI Extends Contract with Lilly II-33
Invitrogen to Collaborate with Tecan II-33
Ranbaxy Forms New Drug Discovery Company II-34
Protagen to Expand Protein Biochips Business II-34
Znomics Expands Facilities for Drug Discovery II-34
Eli Lilly Acquires ICOS Corporation II-35
CMC Announces Acquisition of ICOS Biologics Facility from Eli
Lilly II-35
SurModics Acquires Brookwood II-35
Commonwealth Biotechnologies Acquires Tripos Discovery Research II-36
VASTox Acquires Dextra Laboratories and Daniolabs II-36
Takeda Completes Acquisition of Paradigm II-37
Wyeth Completes the Acquisition of Haptogen II-37
Roche Takes Over Nimblegen II-38
AMRI Acquires Pharmaceutical Manufacturing Units in India II-38
Morvus Acquires Cardiff Biologicals and ProTides II-39
Agilent Technologies Acquires Stratagene II-39
AstraZeneca Takes Over MedImmune II-40
Ocimum Acquires Gene Logic's Genomics Business II-40
Newsham Genetics Acquires Monsanto Choice Genetics II-40
Evotec Takes Over Combinature Biopharm’s Drug Discovery Unit II-40
BioServe Takes Over Genomics Collaborative II-41
Thomson Takes Over Unleashed Informatics Ltd II-41
Thomson Completes Acquisition of Prous Science II-41
MDS Acquires Molecular Devices II-42
Evotec to Take over Renovis II-42
Ecopia Merges with Caprion II-42
Domainex Merges with NCE Discovery II-43
Thallion Sells Majority Interest in Caprion Proteomics Business II-43
Affymetrix Enters into Licensing Agreement with Empire Genomics II-43
Graffinity Pharmaceuticals Signs Drug Discovery Agreement with
Amgen II-44
ArQule Signs License Deal with Kyowa Hakko II-44
Toshiba, Canon and Others to Join Forces to Develop Biochips II-44
Orion and ChemDiv Enter into Collaborative Deal II-44
Graffinity Enters into Drug Discovery Collaboration with Pfizer II-45
Tata Enterprise Establishes Pharmaceutical Development Centre II-45
Nicholas Piramal Collaborates with Merck II-45
Eksigent Signs Distribution Agreement with Interface Engineering II-46
LEAD Therapeutics Enters Collaboration with Shang Pharma II-46
MDS Pharma Expands Chinese Lab Operations II-46
Ambit Extends Drug Discovery Collaboration with Bristol -
Myers Squibb II-47
PsychoGenics Enters into Agreement with Cephalon for Drug
Discovery II-47
Abbott and Caprion Proteomics Extends Partnership II-47
Agilent Technologies and BioNanomatrix Enters into Collaboration II-48
Evotec Extends Partnership with Boehringer Ingelheim II-48
Evotec and Interprotein Enter into Collaboration II-48
Galapagos Forms Drug Innovation Alliance with AstraZeneca II-48
Proteome Systems and BD Enter into an Agreement II-49
Galapagos Extends Drug Innovation Partnership with Amgen II-49
Dimerix Collaborates with NCDS II-50
ACE BioSciences and CLC Bio Enter into Collaborative Agreement II-50
Ambrx Enters into Strategic Agreement with Merck & Co II-51
Galapagos and Cystic Fibrosis Collaborate for Drug Discovery II-51
BioDiscovery Collaborates with Illumina II-52
Advinus Collaborates with DNDi II-52
Jubilant & Forest Enter into Partnership Deal II-53
Cisbio to Employ Lumi4™ Technology of Lumiphore II-53
Invitrogen Corporation Signs Agreement with Emiliem to Screen
Kinase Inhibitors II-53
AMRI Establishes New Center in India II-54
Actavis Takes Over Abrika II-54
Galapagos Announces Acquisition of Inpharmatica II-54
PerkinElmer Acquires Proteomics Technology from Agilix II-54
BD Finishes Acquisition of GeneOhm II-55
Albany Acquires ComGenex in Hungary II-55
Agilent Acquires Yokogawa II-55
Strand Forms Partnership with Microsoft BioIT Alliance II-56
Nicholas Piramal Signs License Agreement with Morvus Technology II-56
Cellomics and Evotec Sign a Patent License Agreement II-56
PerkinElmer Opens New Technology Center in Shanghai II-56
Affymetrix Acquires ParAllele II-57
Agilent Acquires Computational Biology II-57
MultiCell and Living Cell Enter into a Joint Venture II-57
Fujitsu and Ensemble Enter into Licensing Agreement II-58
Structural GenomiX Modifies Licensing Agreement with Lilly II-58
Provid Enters into Research Services Agreement with Palatin II-58
NascaCell Signs Co-marketing Agreement with DPI II-58
Evotec and P&G Sign Supply Agreement II-58
Invitrogen Signs Collaborative Agreement with NCDS II-58
HistoRx Enters into Collaboration with Eli Lilly II-59
Invitrogen and Applied Biosystems Forge Strategic Alliance II-59
UCB and ChemBridge Form Collaboration in Discovery Chemistry II-59
Pharmacopeia and CV Therapeutics Form Drug Discovery and
Development Collaboration II-59
OriGene Enters into Collaboration with Cytomyx II-60
Discovery Partners Divests Discovery Systems Business to Nexus II-60
CRL Acquires River Valley Farms II-60
Agilent Acquires Silicon II-60
Medarex Acquires Ability Biomedical II-60
National Instruments Enters into Joint Venture Agreement with
Agilent II-61
Amersham Enters into 3-Year Distribution Agreement with Guava II-61
ChemBridge Signs an Agreement with Merck & Co. II-61
Bristol-Myers Collaborates with MEDX II-61
Bayer Enters into Partnership with Physiomics II-61
Pharmacopeia Spins-Off Pharmacopeia Drug Discovery II-61
Abbott Enters into Collaboration with Caprion II-62
Vertex Divests Instrumentation Assets to Aurora II-62

7. Focus on Select Global Players II-63
Abbott Laboratories (US) II-63
Affymetrix Inc. (US) II-63
Agilent Technologies Inc. (US) II-63
Albany Molecular Research, Inc. (US) II-63
Amersham Biosciences (US) II-64
Applera Corporation (US) II-64
ArQule Inc. (US) II-64
AstraZeneca (UK) II-64
BD Biosciences (US) II-65
Bio-Rad Laboratories, Inc. (US) II-65
BioSciences Group (Japan) II-65
Caliper Life Sciences, Inc. (US) II-65
Capital GenomiX (US) II-66
Caprion Proteomics (Canada) II-66
Charles River Laboratories International, Inc. (US) II-66
ChemBridge Corporation (US) II-66
deCODE Genetics, Inc (Iceland) II-66
Evotec AG (Germany) II-67
Galapagos NV (Belgium) II-67
Incyte Corporation (Formerly Incyte Genomics Inc.) (US) II-67
Infinity Pharmaceuticals, Inc. (US) II-67
Invitrogen Corporation (US) II-67
Medarex, Inc. (US) II-68
Merck & Co., Inc. (US) II-68
Millennium Pharmaceuticals, Inc. (US) II-68
National Center for Drug Screening (China) II-68
PerkinElmer, Inc. (US) II-68
Pharmacopeia Inc. (US) II-68
Proteome Systems (Australia) II-69
Quantum Pharmaceuticals (Russia) II-69
Shimadzu Corporation (Japan) II-69
Sigma-Aldrich (US) II-69
Tecan Group (Switzerland) II-69
Thallion Pharmaceuticals, Inc. (Canada) II-70
Tripos International (US) II-70

8. Global Market Perspective II-71
Table 1: World Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Geographic Region - US, Canada,
Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-71

Table 2: World Long-term Projections for Drug Discovery
Technologies by Geographic Region - US, Canada, Japan, Europe
and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-72

Table 3: World 10-Year Perspective for Drug Discovery
Technologies by Geographic Region - Percentage Breakdown of
Value Sales for US, Canada, Japan, Europe and Rest of World
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-73
Analytics by Drug Discovery Technology Type II-74
Table 4: World Recent Past, Current & Future Analysis for
Bioanalytical Instruments by Geographic Region - US, Canada,
Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-74

Table 5: World Long-term Projections for Bioanalytical
Instruments by Geographic Region - US, Canada, Japan, Europe
and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-75

Table 6: World 10-Year Perspective for Bioanalytical
Instruments by Geographic Region - Percentage Breakdown of
Value Sales for US, Canada, Japan, Europe and Rest of World
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-76

Table 7: World Recent Past, Current & Future Analysis for High
Throughput Screening (HTS) by Geographic Region - US, Canada,
Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-77

Table 8: World Long-term Projections for High Throughput
Screening (HTS) by Geographic Region - US, Canada, Japan,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) II-78

Table 9: World 10-Year Perspective for High Throughput
Screening (HTS) by Geographic Region - Percentage Breakdown of
Value Sales for US, Canada, Japan, Europe and Rest of World
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-79

Table 10: World Recent Past, Current & Future Analysis for
Biochip by Geographic Region - US, Canada, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-80

Table 11: World Long-term Projections for Biochip by
Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-81

Table 12: World 10-Year Perspective for Biochip by Geographic
Region - Percentage Breakdown of Value Sales for US, Canada,
Japan, Europe and Rest of World Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-82

Table 13: World Recent Past, Current & Future Analysis for
Proteomics by Geographic Region - US, Canada, Japan, Europe
and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-83

Table 14: World Long-term Projections for Proteomics by
Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-84

Table 15: World 10-Year Perspective for Proteomics by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe and Rest of World Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) II-85

Table 16: World Recent Past, Current & Future Analysis for
Genomics by Geographic Region - US, Canada, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-86

Table 17: World Long-term Projections for Genomics by
Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-87

Table 18: World 10-Year Perspective for Genomics by Geographic
Region - Percentage Breakdown of Value Sales for US, Canada,
Japan, Europe and Rest of World Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-88

Table 19: World Recent Past, Current & Future Analysis for
Bioinformatics by Geographic Region - US, Canada, Japan,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-89

Table 20: World Long-term Projections for Bioinformatics by
Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-90

Table 21: World 10-Year Perspective for Bioinformatics by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe and Rest of World Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) II-91

Table 22: World Recent Past, Current & Future Analysis for
Pharmacogenomics by Geographic Region - US, Canada, Japan,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-92

Table 23: World Long-term Projections for Pharmacogenomics by
Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-93

Table 24: World 10-Year Perspective for Pharmacogenomics by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe and Rest of World Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) II-94

Table 25: World Recent Past, Current & Future Analysis for
Other Drug Discovery Technologies by Geographic Region - US,
Canada, Japan, Europe and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2001
through 2010 (includes corresponding Graph/Chart) II-95

Table 26: World Long-term Projections for Other Drug Discovery
Technologies by Geographic Region - US, Canada, Japan, Europe
and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-96

Table 27: World 10-Year Perspective for Other Drug Discovery
Technologies by Geographic Region - Percentage Breakdown of
Value Sales for US, Canada, Japan, Europe and Rest of World
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-97


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Overview III-1
US Leads the World High Throughput Screening (HTS) Market III-1
Current & Future Analysis III-2
Product Launches III-2
Strategic Corporate Developments III-9
Focus on Select US Players III-28
Abbott Laboratories III-28
Affymetrix Inc. III-28
Agilent Technologies Inc. III-28
Albany Molecular Research, Inc. III-28
Amersham Biosciences III-29
Applera Corporation III-29
ArQule Inc. III-29
BD Biosciences III-30
Bio-Rad Laboratories, Inc. III-30
Caliper Life Sciences, Inc. III-30
Capital GenomiX III-30
Charles River Laboratories International, Inc. III-31
ChemBridge Corporation III-31
deCODE Genetics, Inc. III-31
HistoRx, Inc. III-31
Incyte Corporation (Formerly Incyte Genomics Inc.) III-31
Infinity Pharmaceuticals, Inc. III-32
Invitrogen Corporation III-32
Medarex, Inc. III-32
Merck & Co., Inc. III-32
Millennium Pharmaceuticals, Inc. III-32
PerkinElmer, Inc. III-32
Pharmacopeia Inc.. III-33
Provid Pharmaceuticals, Inc. III-33
Tigris Pharmaceuticals, Inc. III-33
Sigma-Aldrich III-33
Tripos International. III-33
B.Market Analytics III-34
Table 28: US Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Technology Type - Bioanalytical
Instruments, HTS, Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics and Other Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2001 through 2010 (includes corresponding Graph/Chart) III-34

Table 29: US Long-term Projections for Drug Discovery
Technologies by Technology Type - Bioanalytical Instruments,
High Throughput Screening (HTS), Biochip, Proteomics,
Genomics, Bioinformatics, Pharmacogenomics and Other Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-35

Table 30: US 10-Year Perspective for Drug Discovery
Technologies by Technology Type - Percentage Breakdown of
Value Sales for Bioanalytical Instruments, HTS, Biochip,
Proteomics, Genomics, Bioinformatics, Pharmacogenomics and
Other Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-36

2. Canada III-37
A.Market Analysis III-37
Current & Future Analysis III-37
Strategic Corporate Developments III-37
Focus on Select Canadian Players III-38
Caprion Proteomics III-38
Thallion Pharmaceuticals, Inc. III-38
B.Market Analytics III-39
Table 31: Canadian Recent Past, Current & Future Analysis
for Drug Discovery Technologies by Technology Type -
Bioanalytical Instruments, High Throughput Screening (HTS),
Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics and Other Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-39

Table 32: Canadian Long-term Projections for Drug Discovery
Technologies by Technology Type - Bioanalytical Instruments,
High Throughput Screening (HTS), Biochip, Proteomics,
Genomics, Bioinformatics, Pharmacogenomics and Other Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-40

Table 33: Canadian 10-Year Perspective for Drug Discovery
Technologies by Technology Type - Percentage Breakdown of
Value Sales for Bioanalytical Instruments, High Throughput
Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics and Other Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-41

3. Japan III-42
A.Market Analysis III-42
Current & Future Analysis III-42
Japan Resembles US in Life Science Research III-42
Strategic Corporate Developments III-42
Focus on Select Japanese Players III-43
BioSciences Group III-43
Shimadzu Corporation III-43
B.Market Analytics III-44
Table 34: Japanese Recent Past, Current & Future Analysis
for Drug Discovery Technologies by Technology Type -
Bioanalytical Instruments, High Throughput Screening (HTS),
Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics and Other Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-44

Table 35: Japanese Long-term Projections for Drug Discovery
Technologies by Technology Type - Bioanalytical Instruments,
High Throughput Screening (HTS), Biochip, Proteomics,
Genomics, Bioinformatics, Pharmacogenomics and Other Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-45

Table 36: Japanese 10-Year Perspective for Drug Discovery
Technologies by Technology Type - Percentage Breakdown of
Value Sales for Bioanalytical Instruments, High Throughput
Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics and Other Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-46

4. Europe III-47
A.Market Analysis III-47
Current & Future Analysis III-47
An Overview of Pharmacogenomics and Personalized Medicine III-47
Emerging Trends in Proteomics Technology III-48
Protein Classification III-48
Protein Separation III-49
Market Trends III-50
European Market for Drug Discovery Tools III-50
UK Government Supports Proteomics Research III-50
Drug Discovery Outsourcing in Europe III-50
Recent Industry Activity III-51
Focus on Select European Players III-60
AstraZeneca (UK) III-60
deCODE Genetics, Inc (Iceland) III-60
Evotec AG (Germany) III-60
NascaCell IP GmbH (Germany) III-60
Quantum Pharmaceuticals (Russia) III-61
Tecan Group (Switzerland) III-61
UCB (Belgium) III-61
B.Market Analytics III-62
Table 37: European Recent Past, Current & Future Analysis
for Drug Discovery Technologies by Technology Type -
Bioanalytical Instruments, High Throughput Screening (HTS),
Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics and Other Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-62

Table 38: European Long-term Projections for Drug Discovery
Technologies by Technology Type - Bioanalytical Instruments,
High Throughput Screening (HTS), Biochip, Proteomics,
Genomics, Bioinformatics, Pharmacogenomics and Other Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-63

Table 39: European 10-Year Perspective for Drug Discovery
Technologies by Technology Type - Percentage Breakdown of
Value Sales for Bioanalytical Instruments, High Throughput
Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics and Other Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-64

5. Rest of World III-65
A.Market Analysis III-65
Current & Future Analysis III-65
Asia-Pacific III-65
Emerging Opportunities III-65
Cost Advantage in Asia Attracts Global Drug Discovery Industry III-65
Regulations Affect Asia-Pacific Drug Discovery Market III-65
India III-66
Bioinformatics Market in India III-66
Scope and Demand for Bioinformatics Market to Expand
Significantly by 2010 III-66
Discovery of Therapeutic Molecules - A New Buzzword for
Growth Acceleration III-67
Strategic Corporate Developments III-68
Focus on Select Players III-75
National Center for Drug Screening (China) III-75
Proteome Systems (Australia) III-75
B.Market Analytics III-76
Table 40: Rest of World Recent Past, Current & Future
Analysis for Drug Discovery Technologies by Technology Type
- Bioanalytical Instruments, High Throughput Screening
(HTS), Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics & Other Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) III-76

Table 41: Rest of World Long-term Projections for Drug
Discovery Technologies by Technology Type - Bioanalytical
Instruments, High Throughput Screening (HTS), Biochip,
Proteomics, Genomics, Bioinformatics, Pharmacogenomics and
Other Markets Independently Analyzed with Annual Sales in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-77

Table 42: Rest of World 10-Year Perspective for Drug
Discovery Technologies by Technology Type - Percentage
Breakdown of Value Sales for Bioanalytical Instruments, High
Throughput Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics and Other Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-78


IV. COMPETITIVE LANDSCAPE